CN100406440C - 含磺酰胺的吲哚化合物结晶及其制造方法 - Google Patents

含磺酰胺的吲哚化合物结晶及其制造方法 Download PDF

Info

Publication number
CN100406440C
CN100406440C CNB2004800260696A CN200480026069A CN100406440C CN 100406440 C CN100406440 C CN 100406440C CN B2004800260696 A CNB2004800260696 A CN B2004800260696A CN 200480026069 A CN200480026069 A CN 200480026069A CN 100406440 C CN100406440 C CN 100406440C
Authority
CN
China
Prior art keywords
cyano group
crystallization
methyl
indole
benzsulfamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800260696A
Other languages
English (en)
Chinese (zh)
Other versions
CN1849305A (zh
Inventor
高桥恵子
林宪司
阿部太一
大前贵生
加藤隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd, Eisai Co Ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN1849305A publication Critical patent/CN1849305A/zh
Application granted granted Critical
Publication of CN100406440C publication Critical patent/CN100406440C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB2004800260696A 2003-09-10 2004-09-01 含磺酰胺的吲哚化合物结晶及其制造方法 Expired - Fee Related CN100406440C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP318953/2003 2003-09-10
JP2003318953 2003-09-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101667949A Division CN101165049A (zh) 2003-09-10 2004-09-01 含磺酰胺的吲哚化合物结晶

Publications (2)

Publication Number Publication Date
CN1849305A CN1849305A (zh) 2006-10-18
CN100406440C true CN100406440C (zh) 2008-07-30

Family

ID=34308544

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2004800260696A Expired - Fee Related CN100406440C (zh) 2003-09-10 2004-09-01 含磺酰胺的吲哚化合物结晶及其制造方法
CNA2007101667949A Pending CN101165049A (zh) 2003-09-10 2004-09-01 含磺酰胺的吲哚化合物结晶

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007101667949A Pending CN101165049A (zh) 2003-09-10 2004-09-01 含磺酰胺的吲哚化合物结晶

Country Status (24)

Country Link
US (2) US7754894B2 (https=)
EP (1) EP1666463B1 (https=)
JP (1) JP4435090B2 (https=)
KR (1) KR20060120644A (https=)
CN (2) CN100406440C (https=)
AT (1) ATE486849T1 (https=)
AU (1) AU2004272400B2 (https=)
BR (1) BRPI0414314A (https=)
CA (1) CA2536995C (https=)
CY (1) CY1110975T1 (https=)
DE (1) DE602004029907D1 (https=)
DK (1) DK1666463T3 (https=)
ES (1) ES2354286T3 (https=)
HR (1) HRP20100631T1 (https=)
IL (2) IL174059A0 (https=)
MX (1) MXPA06002732A (https=)
NO (1) NO335256B1 (https=)
NZ (1) NZ546111A (https=)
PL (1) PL1666463T3 (https=)
PT (1) PT1666463E (https=)
RU (1) RU2336269C2 (https=)
SI (1) SI1666463T1 (https=)
TW (1) TW200514770A (https=)
WO (1) WO2005026118A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09316053A (ja) * 1996-05-24 1997-12-09 Eisai Co Ltd スルホンアミド誘導体の製造法および中間体
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
WO2002036117A1 (en) * 2000-10-31 2002-05-10 Eisai Co., Ltd. Medicinal compositions for concominant use as anticancer atent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007249A (es) * 2000-02-03 2002-12-09 Eisai Co Ltd Inhibidor de la expresion de integrina.
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09316053A (ja) * 1996-05-24 1997-12-09 Eisai Co Ltd スルホンアミド誘導体の製造法および中間体
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
WO2002036117A1 (en) * 2000-10-31 2002-05-10 Eisai Co., Ltd. Medicinal compositions for concominant use as anticancer atent

Also Published As

Publication number Publication date
CA2536995C (en) 2013-12-17
EP1666463A1 (en) 2006-06-07
PT1666463E (pt) 2011-01-17
WO2005026118A1 (ja) 2005-03-24
CY1110975T1 (el) 2015-06-11
HRP20100631T1 (hr) 2010-12-31
EP1666463A4 (en) 2007-12-12
JP4435090B2 (ja) 2010-03-17
JPWO2005026118A1 (ja) 2007-11-08
MXPA06002732A (es) 2006-06-05
TW200514770A (en) 2005-05-01
BRPI0414314A (pt) 2006-10-31
US20090247768A1 (en) 2009-10-01
US7754894B2 (en) 2010-07-13
ATE486849T1 (de) 2010-11-15
DE602004029907D1 (de) 2010-12-16
CA2536995A1 (en) 2005-03-24
IL196569A0 (en) 2011-07-31
CN101165049A (zh) 2008-04-23
AU2004272400A1 (en) 2005-03-24
US20070082941A1 (en) 2007-04-12
ES2354286T3 (es) 2011-03-11
DK1666463T3 (da) 2010-12-20
KR20060120644A (ko) 2006-11-27
IL174059A0 (en) 2006-08-01
NZ546111A (en) 2008-11-28
NO20061545L (no) 2006-06-09
PL1666463T3 (pl) 2011-04-29
RU2006111454A (ru) 2006-08-27
SI1666463T1 (sl) 2011-02-28
HK1092796A1 (en) 2007-02-16
TWI349663B (https=) 2011-10-01
EP1666463B1 (en) 2010-11-03
AU2004272400B2 (en) 2010-03-04
CN1849305A (zh) 2006-10-18
NO335256B1 (no) 2014-10-27
RU2336269C2 (ru) 2008-10-20

Similar Documents

Publication Publication Date Title
JP7047772B2 (ja) Ｂｒｋ阻害化合物
TW201427956A (zh) Ｍｅｋ抑制劑之製備及包含ｍｅｋ抑制劑之調配物
CN113788824A (zh) 吡啶化合物
EP3805229B1 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
BR112021000950A2 (pt) derivados substituídos de triazolo quinoxalina
CN100406440C (zh) 含磺酰胺的吲哚化合物结晶及其制造方法
EP2542548A1 (en) Process for preparation of polymorphic form and new polymorphic form of imatinib mesylate isolated in that process
KR101065984B1 (ko) 테모졸로마이드 에스테르를 포함하는 약학 조성물
CN101103025B (zh) 5-[2-氨基-4-(2-呋喃基)嘧啶-5-基]-1-甲基吡啶-2(1h)-酮的结晶及其制备方法
EP3088402A1 (en) CRYSTALS (2) OF PYRAZINO[2,1-c][1,2,4]TRIAZINE COMPOUND
WO2006121104A1 (ja) ピペリジン環を有するインドール誘導体の結晶およびその製法
JP2018002644A (ja) （Ｓ）−Ｎ−（４−アミノ−５−（キノリン−３−イル）−６，７，８，９−テトラヒドロピリミド［５，４−ｂ］インドリジン−８−イル）アクリルアミドの結晶
JP7169695B2 (ja) ピラジノ［２，１－ｃ］［１，２，４］トリアジン化合物の結晶（１）
JP2006527235A (ja) １，３，４−トリアザフェナレンおよび１，３，４，６−テトラアザフェナレン誘導体
CN101175751B (zh) 具有哌啶环的吲哚衍生物的晶体和其制备方法
HK1092796B (en) Crystal of sulfonamide-containing indole compound and process for producing the same
CN104557955B (zh) 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
HK40052813A (en) Pyridine salts and process
HK40040064B (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
HK40040064A (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: WEI CAI & D MANAGEMENT CO., LTD.

Free format text: FORMER OWNER: EISAI CO., LTD.

Effective date: 20070202

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070202

Address after: Tokyo, Japan, Japan

Applicant after: Eisai R. & D. Man Co., Ltd.

Address before: Tokyo, Japan, Japan

Applicant before: Eisai co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080730

Termination date: 20170901